HL
HLBBF.US H. Lundbeck A/S
- Market cap
- USD 9.02B
- P/E
- 14.2x
- P/B
- 1.68x
- ROE
- 18.8%
- Dividend yield
- 2.51%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HLBBF.US undervalued?
Graham numberHLBBF.US trades 3.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
H. Lundbeck A/S fundamental analysis
No fundamental analysis for H. Lundbeck A/S yet.
H. Lundbeck A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Ci…
Full company profileH. Lundbeck A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
H. Lundbeck A/S annual financial statements (DKK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.6B | 17.2B | 17.9B | 17.4B | 17.7B | 16.3B | 18.2B | 19.9B | 22.0B | 24.3B | 26.8B |
| Gross Profit | 11.6B | 13.4B | 14.4B | 14.0B | 13.5B | 12.7B | 14.3B | 15.4B | 17.8B | 19.3B | 21.5B |
| Operating Income | 2.29B | 4.41B | 5.30B | 3.61B | 1.99B | 2.01B | 2.85B | 3.20B | 3.27B | 6.33B | 7.83B |
| EBITDA | 4.02B | 5.42B | 6.46B | 4.76B | 4.88B | 3.44B | 4.39B | 5.06B | 5.71B | 7.32B | 9.74B |
| Net Income | 1.21B | 2.62B | 3.91B | 2.31B | 1.58B | 1.32B | 1.92B | 2.29B | 3.14B | 3.18B | 5.39B |
| EPS | 6.13 | 13 | 20 | 12 | 7.96 | 1.33 | 1.93 | 2.31 | 3.17 | 3.21 | 5.43 |
| Balance Sheet | |||||||||||
| Total Assets | 20.2B | 19.8B | 23.0B | 35.8B | 36.0B | 34.7B | 37.5B | 37.4B | 57.0B | 53.9B | 54.5B |
| Total Liabilities | 10.5B | 7.58B | 8.76B | 21.2B | 19.1B | 16.4B | 16.7B | 15.4B | 32.0B | 29.0B | 25.9B |
| Shareholders' Equity | 9.69B | 12.2B | 14.3B | 14.6B | 17.0B | 18.3B | 20.8B | 22.0B | 25.0B | 24.8B | 28.6B |
| Cash & Short-term Investments | 2.22B | 3.68B | 6.64B | 3.01B | 3.92B | 2.28B | 3.42B | 5.01B | 4.66B | 3.43B | 3.72B |
| Total Debt | 1.90B | 57.0M | 72.0M | 9.58B | 7.89B | 5.32B | 5.58B | 4.15B | 16.7B | 11.7B | 8.76B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.13B | 4.05B | 5.98B | 2.61B | 3.84B | 2.27B | 3.52B | 4.08B | 3.33B | 4.89B | 6.60B |
| Capital Expenditure | 342M | 725M | 704M | 444M | 478M | 612M | 820M | 501M | 565M | 553M | 597M |
| Free Cash Flow | 2.78B | 3.32B | 5.28B | 2.17B | 3.36B | 1.66B | 2.70B | 3.58B | 2.76B | 4.33B | 6.00B |
| Ratios | |||||||||||
| ROE | 12.5% | 21.5% | 27.4% | 15.9% | 9.3% | 7.2% | 9.2% | 10.4% | 12.6% | 12.8% | 18.8% |
| ROA | 6.0% | 13.3% | 17.0% | 6.5% | 4.4% | 3.8% | 5.1% | 6.1% | 5.5% | 5.9% | 9.9% |
| Net Profit Margin | 7.7% | 15.2% | 21.9% | 13.3% | 8.9% | 8.1% | 10.5% | 11.5% | 14.3% | 13.1% | 20.1% |
| Debt to Equity | 0.20x | 0.00x | 0.01x | 0.66x | 0.46x | 0.29x | 0.27x | 0.19x | 0.67x | 0.47x | 0.31x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
H. Lundbeck A/S dividends
- Dividend yield
- 2.51%
- Forward dividend
- 0.18 USD
- Payout ratio
- 29.5%
- Ex-dividend date
- Mar 19, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | DKK 941M | 0.95 | 29.5% |
| 2024 | DKK 694M | 0.70 | 22.1% |
| 2023 | USD 576M | 0.58 | 25.2% |
| 2022 | DKK 397M | 0.40 | 20.7% |
| 2021 | USD 497M | 0.50 | 37.7% |
| 2020 | USD 815M | 4.10 | 51.5% |
| 2019 | USD 2.38B | 12 | 103.1% |
| 2018 | USD 1.59B | 8.00 | 40.7% |
| 2017 | USD 483M | 2.44 | 18.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns H. Lundbeck A/S
- Insiders 0.10%
- Institutions 80.81%
- Public & others 19.09%
- Shares outstanding 793M
- Free float 304M
H. Lundbeck A/S company profile
- Company name
- H. Lundbeck A/S
- Ticker
- HLBBF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,000
- Fiscal year end
- December
- Address
- Ottiliavej 9, Valby, Denmark, 2500
- Phone
- 45 36 30 13 11
- Website
- lundbeck.com
About H. Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
H. Lundbeck A/S management
10- Mr. Charl van ZylPresident & CEO · born 1967
- Mr. Joerg HornsteinCFO & Executive VP of Corporate Functions · born 1977
- Dr. Per Johan Luthman Ph.D.Advisor · born 1959
- Dr. Tarek Samad Ph.D.Executive VP and Head of Research & Development
- Jens HoyerVice President & Head of Investor Relations
- Ms. Dianne HoltoExecutive Vice President of People, Culture & Sustainability · born 1973
- Mr. Thomas E. GibbsExecutive VP & Head of Lundbeck in United States · born 1971
- Prof. Johannes Rolf Streffer M.D.Senior VP & Head of Global Clinical Development · born 1969
- Ms. Michala Fischer-HansenExecutive VP and Head of Europe & International Markets and Operations · born 1974
- Ms. Tine Ostergaard HansenSenior Vice President of Corporate Affairs · born 1975